Samus Therapeutics is a privately held Boston-based biopharmaceutical company. Samus is developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders such as Alzheimer’s, Parkinson’s and chronic traumatic encephalopathy.